Kent Holtorf, MD - LDN should be considered a first-line therapy for CFS/FM (2019 Conference) (LDN, low dose naltrexone)

Kent Holtorf, MD - LDN should be considered a first-line therapy for CFS/FM (2019 Conference) (LDN, low dose naltrexone)

Kent Holtorf, MD discusses the multisystem nature and cycle of chronic disorders such as Lyme disease, CFS, fibromyalgia, and ME, and the role that immune dysfunction, inflammation, and TH1-TH2 shift have in such disorders. He presents immune modulating therapies that address multisystem diseases, including LDN and others.